Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$103.54
+0.2%
$109.56
$77.56
$116.04
$25.18B0.682.27 million shs2.06 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$137.87
+2.9%
$130.58
$74.75
$142.00
$53.15B1.22.96 million shs3.24 million shs
McKesson Co. stock logo
MCK
McKesson
$535.56
+0.7%
$526.81
$352.34
$543.00
$70.38B0.45687,556 shs418,139 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
+0.16%-2.80%-6.78%-2.06%+28.01%
DexCom, Inc. stock logo
DXCM
DexCom
+2.89%+3.00%-1.59%+8.98%+11.22%
McKesson Co. stock logo
MCK
McKesson
+0.69%+1.83%+0.57%+10.12%+47.42%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
4.2798 of 5 stars
1.33.03.33.62.51.73.1
DexCom, Inc. stock logo
DXCM
DexCom
4.3933 of 5 stars
1.54.00.04.73.22.53.1
McKesson Co. stock logo
MCK
McKesson
4.8403 of 5 stars
2.45.03.33.03.02.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
2.55
Moderate Buy$103.07-0.45% Downside
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.402.56% Upside
McKesson Co. stock logo
MCK
McKesson
2.83
Moderate Buy$533.50-0.38% Downside

Current Analyst Ratings

Latest MCK, CAH, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
McKesson Co. stock logo
MCK
McKesson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$522.00 ➝ $548.00
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
4/10/2024
McKesson Co. stock logo
MCK
McKesson
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$510.00 ➝ $570.00
4/3/2024
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$148.00 ➝ $161.00
3/12/2024
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$165.00
3/6/2024
McKesson Co. stock logo
MCK
McKesson
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$575.00 ➝ $620.00
2/26/2024
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$125.00
2/26/2024
McKesson Co. stock logo
MCK
McKesson
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024
McKesson Co. stock logo
MCK
McKesson
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$600.00
2/9/2024
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$205.01B0.12$8.74 per share11.84($11.20) per share-9.24
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B14.67$2.17 per share63.56$5.35 per share25.77
McKesson Co. stock logo
MCK
McKesson
$276.71B0.25$32.72 per share16.37($10.99) per share-48.73

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$261M$2.5440.7613.010.990.30%-57.44%3.89%5/2/2024 (Confirmed)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.31105.2561.832.2614.95%28.31%9.74%4/25/2024 (Confirmed)
McKesson Co. stock logo
MCK
McKesson
$3.56B$22.0724.2717.241.430.99%-262.63%5.96%5/7/2024 (Confirmed)

Latest MCK, CAH, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
McKesson Co. stock logo
MCK
McKesson
$6.39N/A-$6.39N/AN/AN/A  
5/2/2024N/A
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$1.96N/A-$1.96N/AN/AN/A  
4/25/2024N/A
DexCom, Inc. stock logo
DXCM
DexCom
$0.27N/A-$0.27N/AN/AN/A  
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      
2/7/2024Q3 2024
McKesson Co. stock logo
MCK
McKesson
$7.05$7.74+$0.69$11.06$77.93 billion$80.90 billion    
2/1/2024Q2 2024
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$1.56$1.82+$0.26$2.21$57.02 billion$57.45 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$2.001.93%+1.00%78.74%27 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
McKesson Co. stock logo
MCK
McKesson
$2.480.46%+11.80%11.24%16 Years

Latest MCK, CAH, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
McKesson Co. stock logo
MCK
McKesson
quarterly$0.620.47%6/3/20247/1/2024
2/6/2024
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
quarterly$0.50061.92%3/28/20244/1/20244/15/2024
2/1/2024
McKesson Co. stock logo
MCK
McKesson
quarterly$0.620.5%2/29/20243/1/20244/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
N/A
0.98
0.50
DexCom, Inc. stock logo
DXCM
DexCom
1.18
2.84
2.48
McKesson Co. stock logo
MCK
McKesson
N/A
0.92
0.50

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
87.17%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
McKesson Co. stock logo
MCK
McKesson
85.07%

Insider Ownership

CompanyInsider Ownership
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
0.15%
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
McKesson Co. stock logo
MCK
McKesson
0.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
48,000243.23 million242.87 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600385.52 million383.93 millionOptionable
McKesson Co. stock logo
MCK
McKesson
51,000131.41 million131.13 millionOptionable

MCK, CAH, and DXCM Headlines

SourceHeadline
Leerink Partnrs Weighs in on McKesson Co.s Q3 2025 Earnings (NYSE:MCK)Leerink Partnrs Weighs in on McKesson Co.'s Q3 2025 Earnings (NYSE:MCK)
americanbankingnews.com - April 25 at 2:36 AM
Wynn Capital LLC Invests $1.98 Million in McKesson Co. (NYSE:MCK)Wynn Capital LLC Invests $1.98 Million in McKesson Co. (NYSE:MCK)
marketbeat.com - April 24 at 6:36 PM
Outperforming Pharma Stock Ready To Run HigherOutperforming Pharma Stock Ready To Run Higher
forbes.com - April 24 at 1:47 PM
McKesson Co. to Issue Quarterly Dividend of $0.62 (NYSE:MCK)McKesson Co. to Issue Quarterly Dividend of $0.62 (NYSE:MCK)
marketbeat.com - April 24 at 10:36 AM
Barclays Reaffirms Their Buy Rating on McKesson (MCK)Barclays Reaffirms Their Buy Rating on McKesson (MCK)
markets.businessinsider.com - April 24 at 8:46 AM
McKesson Corporation Declares Quarterly DividendMcKesson Corporation Declares Quarterly Dividend
businesswire.com - April 24 at 8:00 AM
Q3 2025 EPS Estimates for McKesson Co. (NYSE:MCK) Raised by AnalystQ3 2025 EPS Estimates for McKesson Co. (NYSE:MCK) Raised by Analyst
marketbeat.com - April 24 at 6:49 AM
SCOTUS should be protecting protesters’ rights | Not to Get Political ButSCOTUS should be protecting protesters’ rights | Not to Get Political But
dailyfreepress.com - April 24 at 3:46 AM
Q2 2025 EPS Estimates for McKesson Co. Raised by Leerink Partnrs (NYSE:MCK)Q2 2025 EPS Estimates for McKesson Co. Raised by Leerink Partnrs (NYSE:MCK)
americanbankingnews.com - April 24 at 2:44 AM
VIDEO: Maryland officer hits suspect 8 times in head after being spat onVIDEO: Maryland officer hits suspect 8 times in head after being spat on
wpde.com - April 23 at 10:45 PM
BLM activist DeRay McKesson still hounded by wild lawsuitBLM activist DeRay McKesson still hounded by 'wild' lawsuit
baltimoresun.com - April 23 at 5:45 PM
McKesson Co. (NYSE:MCK) Shares Sold by New York State Common Retirement FundMcKesson Co. (NYSE:MCK) Shares Sold by New York State Common Retirement Fund
marketbeat.com - April 23 at 12:28 PM
Q2 2025 Earnings Estimate for McKesson Co. Issued By Leerink Partnrs (NYSE:MCK)Q2 2025 Earnings Estimate for McKesson Co. Issued By Leerink Partnrs (NYSE:MCK)
marketbeat.com - April 23 at 6:31 AM
Buy Rating Affirmed: McKesson’s Strategic Growth Bolstered by OptumRx Contract WinBuy Rating Affirmed: McKesson’s Strategic Growth Bolstered by OptumRx Contract Win
markets.businessinsider.com - April 23 at 3:10 AM
The Supreme Court Declined a Protestors Rights Case. Heres What You Need to Know.The Supreme Court Declined a Protestors' Rights Case. Here's What You Need to Know.
aclu.org - April 22 at 10:10 PM
Wedge Capital Management L L P NC Sells 9,263 Shares of McKesson Co. (NYSE:MCK)Wedge Capital Management L L P NC Sells 9,263 Shares of McKesson Co. (NYSE:MCK)
marketbeat.com - April 22 at 6:08 PM
Car­di­nal Health los­es Op­tum­Rx con­tract to McKessonCar­di­nal Health los­es Op­tum­Rx con­tract to McKesson
endpts.com - April 22 at 5:07 PM
The Top 3 Healthcare Stocks to Buy in April 2024The Top 3 Healthcare Stocks to Buy in April 2024
investorplace.com - April 22 at 4:02 PM
Drug distributor Cardinal Health to lose OptumRx contractsDrug distributor Cardinal Health to lose OptumRx contracts
msn.com - April 22 at 12:05 PM
Ardevora Asset Management LLP Has $10.36 Million Stock Position in McKesson Co. (NYSE:MCK)Ardevora Asset Management LLP Has $10.36 Million Stock Position in McKesson Co. (NYSE:MCK)
marketbeat.com - April 21 at 9:14 PM
McKesson Co. (NYSE:MCK) Given Average Rating of "Moderate Buy" by AnalystsMcKesson Co. (NYSE:MCK) Given Average Rating of "Moderate Buy" by Analysts
americanbankingnews.com - April 21 at 2:30 AM
Pilot program seeking support to provide housing, food and transportation for DFW cancer patientsPilot program seeking support to provide housing, food and transportation for DFW cancer patients
msn.com - April 20 at 7:32 PM
McKesson Co. (NYSE:MCK) Shares Sold by Federated Hermes Inc.McKesson Co. (NYSE:MCK) Shares Sold by Federated Hermes Inc.
marketbeat.com - April 20 at 7:16 AM
Jeopardizing the right to protest, Supreme Court refuses to block lawsuit by police officer against demonstration organizerJeopardizing the right to protest, Supreme Court refuses to block lawsuit by police officer against demonstration organizer
wsws.org - April 19 at 10:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Cardinal Health logo

Cardinal Health

NYSE:CAH
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
McKesson logo

McKesson

NYSE:MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.